オプションチェーンは、Amrizeの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Amrizeの市場センチメントを評価します。.

Amrize (NYSE:AMRZ) 株価情報, オプションチェーン

Amrize Ltd is a building solutions company focused exclusively on the North American market, offering customers a broad range of advanced building solutions from foundation to rooftop. The Company earns revenue from the sale of cement, aggregates, ready-mix concrete, asphalt, roofing systems and other building solutions. The Company is organized into two reportable segments - Building Materials and Building Envelope. The building materials segment offers a range of branded solutions delivering high-quality products for a wide range of applications. The building envelope segment offers advanced roofing and wall systems, including single-ply membranes, insulation, shingles, sheathing, waterproofing and protective coatings, along with adhesives, tapes and sealants.

Amrize Ltd

Arena Minerals Inc

News

BMBL

Bumble Says Reducing Size Of Team

WIIM

ASTS

AST SpaceMobile shares are trading lower after the company announced a registered direct offering to sell 9.45 million shares at $53.22 per share.

Wearable Devices Ltd. (the "Company" or "Wearable Devices") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLDS#NASDAQ">WLDS</a>, WLDSW))), a technology growth company specializing in artificial intelligence ("AI")-powered touchless sensing wearables, recently announced the expansion of its Large Motor Unit Action Potential Model ("LMM") into new potential markets, such as predictive health monitoring and cognitive state analytics. This development will enable the broadening of bio-signal intelligence applications beyond wearables and will offer businesses and healthcare providers access to real-time physiological insights for monitoring health and wellness conditions.
This strategic expansion into predictive health monitoring aligns with the rising interest in personalized wellness devices. This interest is now demonstrated at the federal level. U.S. Secretary of Health and Human Services, Robert F. Kennedy Jr., has recently advocated for wearable devices to enhance health monitoring and cognitive well-being, underscoring the public and institutional momentum toward real-time data-driven care.
This announcement follows Wearable Devices' recent introduction of LMM as a groundbreaking AI-driven bio-signal platform focused on gesture-based control in extended reality ("XR") and neural interaction with digital devices. The Company's LMM approach to analyzing muscle activity signals will support the expansion into the field of health monitoring, enabling users to enhance their performance across various domains.
From Passive Monitoring to Proactive Intelligence
Unlike traditional bio-sensors that collect data passively, LMM continuously learns and adapts, turning muscle activity signals from the wrist into actionable insights. The technology is now being evaluated in controlled environments for real-world applications, including:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>●</td>
<td>Predictive Health Monitoring&nbsp;- Detecting hidden patterns in muscle activity that may indicate early signs of health conditions before symptoms appear, revolutionizing preventive diagnostics and digital health tracking.</td>
</tr>
<tr>
<td>●</td>
<td>Cognitive State &amp; Performance Analytics&nbsp;- Monitoring focus, fatigue, and stress levels through muscle tone and micro-movements, optimizing work productivity and mental well-being.</td>
</tr>
<tr>
<td>●</td>
<td>Exploring Predictive Analytics -&nbsp;Assessing whether continuous monitoring of neural data can improve AI-driven user behavior predictions.</td>
</tr>
</tbody>
</table>
</figure>
A Platform for Innovation: Opening LMM to Business Partners
Recognizing the transformative potential of bio-signal intelligence, Wearable Devices is intending to make LMM available to enterprises, researchers, and developers. The Company's AI-powered bio-signal data platform is expected to enable businesses to:
&nbsp;

WLDS

Wearable Devices Announces Expansion Of Its Large Motor Unit Action Potential Model Into New Potential Markets Including Predictive Health Monitoring And Cognitive State Analytics

Goldman Sachs analyst Carly Davenport upgrades Ameren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEE#NYSE">AEE</a>) from Sell to Neutral and raises the price target from $91 to $100.

Upgrades

Price Target

Analyst Ratings

Goldman Sachs Upgrades Ameren to Neutral, Raises Price Target to $100

Registered Direct Offering
AST SpaceMobile has agreed to sell an aggregate of 9,450,268 shares of its Class A common stock in the Registered Direct Offering at a price of $53.22 per share to holders of the 2032 convertible notes participating in the Repurchase.

Offerings

AST SpaceMobile Announces Registered Direct Offering To Sell 9.45M Shares At $53.22 Each To 2032 Noteholders

Chardan Capital analyst James McIlree maintains Cleanspark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>) with a Buy and maintains $20 price target.

CLSK

Chardan Capital Maintains Buy on Cleanspark, Maintains $20 Price Target

Goldman Sachs analyst Carly Davenport downgrades WEC Energy Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEC#NYSE">WEC</a>) from Neutral to Sell and lowers the price target from $106 to $100.

Downgrades

Goldman Sachs Downgrades WEC Energy Group to Sell, Lowers Price Target to $100

QXO shares are trading lower after the company announced the pricing of its offering of 89,887,640 shares at $22.25 per share.

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer recommended owning MP Materials Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>), adding that he has always <a href="https://www.benzinga.com/quote/MP/earnings">liked the stock</a>.
Supporting his view, Baird analyst Ben Kallo, on June 17, maintained MP Materials with an Outperform rating and raised the price target from&nbsp;$30&nbsp;to&nbsp;$38.
When asked about Six Flags Entertainment Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUN#NYSE">FUN</a>), he said, &#8220;Don't be interested in it. I don't like the theme parks other than Disney (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>).&#8221;
Supporting his view, Six Flags Entertainment, on May 8, reported worse-than-expected first-quarter sales results.
&#8220;I'm not going to fight anyone who wants to own a nuclear stock. I'm going to bless it even though it's up very, very big,&#8221; Cramer said when asked about BWX Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWXT#NYSE">BWXT</a>).
As per the recent news, BWXT, on June 16, named Kevin McCoy as chief nuclear officer to advance U.S. Navy submarine programs.
Cramer said he is again going to bless Jabil Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>). &#8220;It's the kind of company you need to deal with right now — they'll understand all the tariff problems, and they'll help you,&#8221; he added.
Lending support to his choice, Jabil posted third-quarter results on June 17 that exceeded analyst expectations for earnings per share and sales. Jabil also announced an investment of approximately $500 million over the next several years to expand its footprint in the Southeast United States.
Price Action:
<ul class="wp-block-list">
<li>Six Flags shares settled at $30.49 on Tuesday.</li>
<li>MP Materials shares dipped 4.5% to close at $34.91.</li>
<li>BWX Technologies gained 0.2% to settle at $142.31 on Tuesday.</li>
<li>Jabil shares rose 1.7% to close at $211.95.</li>
</ul>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46072226/top-3-real-estate-stocks-you-may-want-to-dump-in-june">Top 3 Real Estate Stocks You May Want To Dump In June</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Trading Ideas

BWXT

Why Cramer Thinks Jabil Is The Perfect Stock For A Tariff Storm

CORRECTION: Stryker Ticker Is 'SYK'

Stryker Announces FDA Clearance For Incompass Total Ankle System

Goldman Sachs analyst Carly Davenport upgrades Duke Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>) from Neutral to Buy and raises the price target from $125 to $132.

Goldman Sachs Upgrades Duke Energy to Buy, Raises Price Target to $132

Contineum Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNM#NASDAQ">CTNM</a>) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&amp;I) indications, today announced an update on its Phase 1b positron emission tomography (PET) trial of PIPE-791, a selective antagonist of the lysophosphatidic acid 1 (LPA1) receptor. The Company has completed enrollment of the healthy volunteer and progressive multiple sclerosis (PrMS) cohorts of this trial. The screening and enrollment of idiopathic pulmonary fibrosis (IPF) patients to participate in this trial is ongoing.

Biotech

General

CTNM

Contineum Therapeutics Completes PrMS And Healthy Volunteer Enrollment In Phase 1b PET Trial Of PIPE-791

Novagold Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NG#AMEX">NG</a>) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.03) by 33.33 percent. This is unchanged from the same period last year.

Earnings

Earnings Misses

Novagold Resources Q2 Adj. EPS $(0.04) Misses $(0.03) Estimate

SeaStar Medical Holding Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>) a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today that it has undertaken a series of transactions to ensure compliance with Nasdaq's continued listing standards.&nbsp;&nbsp;
Last year on June 24, 2024, SeaStar Medical received a written notification from Nasdaq's Listing Qualifications Staff that it was not in compliance with the requirement to maintain a minimum market value of listed securities of $35 million as required by Nasdaq Listing Rule 5550(b)(2). After a hearing before the Nasdaq Hearings Panel (the "Panel"), the Panel granted the Company an extension through June 22, 2025, to evidence compliance with the alternative requirement of $2.5 million in stockholders' equity.
SeaStar Medical has completed the following capital transactions and operational improvements to evidence compliance with the Nasdaq equity rule:
Fundraising transactions:
<ul>
<li>On June 23, 2025, SeaStar Medical completed a $4.0 million public offering of common stock and warrants.</li>
<li>On April 25, 2025, SeaStar Medical entered into a purchase agreement with Lincoln Park Capital, pursuant to which Lincoln Park agreed to purchase up to an aggregate of $15.0 million of our common stock from time to time over a three-year term.</li>
</ul>
Revenue generation:
<ul>
<li>In the second fiscal quarter, SeaStar Medical continued to advance its business plan by increasing its customer count to six for the Company's FDA approved product, QUELIMMUNE, which is used by ICU physicians treating pediatric patients with multiple organ failure. QUELIMMUNE has been shown to reduce pediatric mortality by approximately 50% and completely relieve pediatric patients from a lifetime of dialysis. &nbsp;</li>
</ul>
Operating expense reduction:
<ul>
<li>In May 2025, SeaStar Medical began a cost cutting program that is expected to reduce operating expenses for the remainder of the current fiscal year. The Company does not anticipate that these expense reductions will have a material impact on operations. &nbsp;</li>
</ul>
Liability restructuring:
<ul>
<li>In May and June of 2025, approximately $1.2 million of employee compensation and director fee liabilities were extinguished as certain employees and directors waived their rights to bonuses and fees that had accrued but not paid. &nbsp;</li>
</ul>
Based on the above, SeaStar Medical believes it has regained compliance with the $2.5 million stockholders' equity requirement for continued listing on The Nasdaq Capital Market.&nbsp;&nbsp; However, the Company awaits Nasdaq's formal confirmation of compliance.

SeaStar Medical Undertakes Strategic Transactions Including Fundraising Transactions, Revenue Generation, Operating Expense Reduction And Liability Restructuring, To Regain Nasdaq Compliance, Awaits Confirmation

We Energies  To Extend Operating Lives Of Units 7 And 8 At Oak Creek Power Plant Through End Of 2026, Postponing Retirement Date From End Of 2025

<ul>
<li>Initial computational analysis demonstrated that Evaxion's AI-Immunology&#x2122; platform can identify novel vaccine targets to combat Group A Streptococcus (GAS)</li>
<li>New vaccine program is added to Evaxion's pipeline under the name EVX-B4</li>
<li>Urgent need for preventive measures against GAS underscores the significant medical and commercial potential of EVX-B4</li>
<li>Addition of a novel infectious disease candidate to the pipeline is in line with Evaxion's partnership strategy</li>
</ul>
COPENHAGEN, Denmark, June 25, 2025 - Evaxion A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVAX#NASDAQ">EVAX</a>) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology&#x2122; powered vaccines, initiates work to develop a new preventive vaccine against Group A Streptococcus (GAS), a bacteria causing hundreds of millions of infections globally each year. Infection carries the risk of several complications including life threatening conditions like rheumatic heart disease and necrotizing fasciitis ("flesh eating bacteria") and less severe yet serious diseases like strep throat and scarlet fever.
The new vaccine program, named EVX-B4, has been added to Evaxion's research &amp; development (R&amp;D) pipeline of cancer and infectious disease vaccine candidates. Initial computational analysis demonstrated that AI-Immunology&#x2122; can identify novel vaccine targets to combat GAS, which could pave the way for a new approach to fight the bacteria. Deploying AI-Immunology&#x2122; allows for fast and effective target discovery, design and validation, accelerating preclinical development of EVX-B4. This work will create a comprehensive preclinical data package to facilitate partnership discussions.
Adding EVX-B4 to the pipeline achieves another of Evaxion's milestones for 2025. Evaxion's R&amp;D pipeline now comprises five specified vaccine candidates for infectious diseases and three for cancer. The build-up of the pipeline supports Evaxion's partnership strategy as we increase the number of assets for out-licensing.

EVAX

Evaxion Initiates Work To Develop New Preventive Vaccine Against Group A Streptococcus; New Vaccine Program Added To Evaxion's Pipeline Under Name EVX-B4

Raymond James Ltd enters into agreement with FNZ to accelerate its digital transformation
&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4456311-1&amp;h=3952077249&amp;u=https%3A%2F%2Fwww.raymondjames.ca%2F&amp;a=Raymond+James+Ltd.">Raymond James Ltd.</a>, the largest independent financial services firm in Canada, today announced a strategic partnership with <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4456311-1&amp;h=2547701680&amp;u=https%3A%2F%2Fwww.fnz.com%2F&amp;a=FNZ">FNZ</a>, a global wealth management platform provider, to deliver its next-generation wealth management platform. Under the agreement, Raymond James Ltd. will make a significant investment to accelerate the digital transformation of its wealth management infrastructure and elevate the advisor and client experience nationwide.
The partnership will see Raymond James Ltd. leverage FNZ's integrated, end-to-end wealth management platform—a deliberate and future-focused investment in modern infrastructure. Designed to deliver AI-powered capabilities, straight-through processing, and advanced digital capabilities, the FNZ platform will strengthen the Raymond James Ltd. unique value proposition.
"As a client-first organization, we took the time to engage with our advisors, branch associates and clients to define the future of wealth management," said Jamie Coulter CEO, Raymond James Ltd. "This isn't just a technology upgrade—it's a quantum leap in the support we provide our advisors in their delivery of exceptional client service. We're listening, investing, and acting to deliver smarter, more connected experiences for our partners and clients."
The new platform is built with a client-centric, digital-first design that improves efficiency, speed and personalization across the full wealth lifecycle. Advisors will gain a modern, intuitive operating environment, enabling more meaningful client engagements. Investors will benefit from improved digital experiences and real-time capabilities, all backed by the highest level of security and performance provided by the FNZ platform.
This strategic investment strengthens Raymond James Ltd.'s position as a premier destination for top-tier advisors across Canada, reinforcing its commitment to innovation, advisor enablement, and exceptional client service.
FNZ partners with more than 650 financial institutions globally on behalf of 26 million end investors and administers with more than US$ 1.7 trillion in assets. FNZ's market-leading technology and infrastructure will significantly enhance Raymond James Ltd.'s offering to advisors with greater flexibility to adapt quickly to changing markets, regulatory requirements, and investor expectations.
Blythe Masters, Group CEO of FNZ, said: "We are delighted to partner with Raymond James Ltd. to deliver a next-generation wealth management platform that will transform the advisor and client experience across Canada. North America is a key market for FNZ, and this partnership reflects our long-term commitment to investing in the region.
We're excited to bring this innovative platform to life and support Raymond James Ltd. in setting a new standard for wealth management in Canada."
Positioning itself as a leader in financial technology and innovation, Raymond James expects to invest approximately US$1 billion globally in FY2025, with a strong emphasis on information security infrastructure including its dedicated Cyber Threat Center.

Comments

Amrize

Amrize (AMRZ) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル